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Abstract 
Many clients who undergo methadone maintenance (MM) treatment for heroin 
and other opiate dependence prefer abstinence from methadone.  Attempts at methadone 
detoxification are often unsuccessful, however, due to distressing physical as well as 
psychological symptoms.  Outcomes from a MM client who voluntarily participated in an 
Acceptance and Commitment Therapy (ACT) – based methadone detoxification program 
are presented. The program consisted of a 1-month stabilization and 5-month gradual 
methadone dose reduction period, combined with weekly individual ACT sessions. Urine 
samples were collected twice weekly to assess for use of illicit drugs. The participant 
successfully completed the program and had favorable drug use outcomes during the 
course of treatment, and at the one-month and one-year follow-ups. Innovative behavior 
therapies, such as ACT, that focus on acceptance of the inevitable distress associated with 
opiate withdrawal may improve methadone detoxification outcomes.    
 
KEYWORDS: Acceptance; mindfulness; psychological flexibility; experimental 
avoidance; Acceptance and Commitment Therapy; opiate dependence; methadone 
detoxification.  
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Using Acceptance and Commitment Therapy during Methadone Dose Reduction: 
Rationale, Treatment Description, and a Case Report 
The burden of illicit opiate use is substantial, including high morbidity and 
mortality rates, health care utilization costs, legal involvement, family discord, and lost 
productivity (Amato, Davoli, Ferri, Growing, & Perucci, 2004). To date, methadone 
maintenance (MM) is the treatment of choice for opiate dependence. Patients typically 
enter MM treatment after heroin or other opiate dependence is well-established, with the 
average length of stay at any particular clinic being 1-2 years (D’Aunno, Folz-Murphy, & 
Lin 1999). Many MM patients transfer from clinic to clinic, however, remaining on 
methadone for many years, and, for some, the remainder of their lives.  MM is a 
successful treatment as it is associated with decreases in client’s illicit drug use and 
health risk behaviors, as well as significant improvement in social functioning (Simpson, 
Joe, & Bracy, 1982).  Yet, MM remains controversial (Magura & Rosenblum, 2001). 
Many professionals believe that substituting one addiction for another is not ethically or 
therapeutically acceptable. In addition, long-term MM treatment incurs significant 
financial burden, restrictions in daily activities, and unpleasant stigma. The majority of 
MM clients state a preference for abstinence (e.g., Lenne et al., 2001), and a number of 
them request detoxification or attempt to detoxify themselves (Latowsky, 1996).  
  The primary obstacle, however, lies in the physical and psychological discomfort 
accompanying methadone detoxification (Magura & Rosenblum, 2001). Withdrawal 
from methadone results in severe and protracted physiological symptoms (e.g., nausea, 
diarrhea, bone pain). Methadone withdrawal experiences are reported to be even more 
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severe than heroin withdrawal (e.g., Gossop & Strang, 1991), with failure to successfully 
taper off methadone being the rule, rather than the exception (Magura & Rosenblum, 
2001). Adverse psychological experiences are also deterrents to detoxification. Most 
prominent is an intense fear related to experiencing detoxification symptoms (e.g., 
Eklund, Hiltunen, Melin, & Borg, 1997). Long before symptoms are physically present, 
anxiety and worry about impending pain and suffering are reported.  Consequently, 
clients who report detoxification phobia are more likely to stay in MM treatment longer 
and make fewer detoxification attempts (Milby et al., 1994). MM clients who have failed 
methadone detoxification report that anticipation or fear of intense withdrawal, rather 
than actual physical symptoms, was the predominant reason for the discontinuation of 
detoxification (Berger & Schwegler, 1973).  
Thus, relapse to opiates or other illicit substances and premature termination of 
detoxification are the most common outcomes especially when clients undergo rapid 
methadone dose reduction in a poorly supervised outpatient setting (Gossop, Marsden, 
Stewart, & Treacy, 2001). Many experts, for this reason, advocate for life-long MM 
treatment. Methadone detoxification is typically patient-initiated and may only be 
recommended to a selected group of clients who have a relatively stable life without the 
current use of illicit drugs. 
Behavioral strategies, such as systematic desensitization (e.g., Hollands & 
Turecek, 1980) and contingency management (e.g., Robles, Stitzer, Strain, Bigelow, & 
Silverman, 2002) have been tested to improve detoxification outcomes. These studies 
revealed equivocal results (e.g., short-term effects), however. Given the inevitability of 
physical and psychological struggles in methadone detoxification, these treatments could 
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possibly be made more effective by teaching clients skills to function more effectively 
while experiencing these difficulties.  In other words, the problem in this context may not 
be simply the presence or intensity of detoxification fears and withdrawal symptoms, but 
the ways in which individuals act on their distressing psychological experiences.  
This line of reasoning overlaps with a contemporary behavioral process purported 
to underlie psychopathology, psychological inflexibility (PI; Hayes, Luoma, Bond, 
Masuda, & Lillis, 2006). Psychological inflexibility is defined as one’s limited and rigid 
behavioral repertoires in the presence of negatively evaluated private events (thoughts, 
feelings, bodily sensation, etc), and is the overarching process targeted by Acceptance 
and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). According to the 
model, the inflexible patterns are due to the domination of unavailing avoidance- and 
control-based coping strategies, collectively referred to as experiential avoidance (Hayes 
et al., 2006). The domination of these behavioral patterns is thought to suppress value-
directed and constructive behaviors. The ACT model suggests that the primary problem 
of negative affect is its function, rather than its existence per se. In other words, these 
events are problematic only because they occasion problematic behavior.  
Research has shown that PI is linked to a wide range of psychological problems 
and functions as a mediator of treatment outcomes (Hayes et al., 2006). Recent studies 
suggest that PI may be a key process involved in the methadone detoxification process. 
Individuals with chronic opiate use tend to have greater fear of anxiety and anxiety-
related sensation (e.g., Lejuez, Paulson, Daughters, Bornovalova, & Zvolensky, 2006). 
Those undergoing MM treatment have less distress tolerance than those who do not have 
substance use problems and display limited behavioral repertoires (i.e., predominantly 
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avoidance strategies) when experiencing negative affect (Compton, Charuvastra, & Ling, 
2001).   
Several studies, ranging from case report studies to randomized controlled trials, 
have shown promising outcomes with ACT in substance use problems (e.g., Gifford et 
al., 2004; Hayes, Wilson, et al., 2004; Twohig, Schoenberger, & Hayes, 2007; Heffner, 
Eifert, Parker, Hernandez, & Sperry, 2003) . In one randomized controlled trial (Gifford 
et al., 2004), ACT was compared to Nicotine Replacement Therapy. Results revealed that 
ACT participants were more likely to remain abstinent at one-year follow-up (35% vs. 
10%). The study also showed that smoking-related PI mediated smoking outcomes, while 
negative affect and withdrawal symptoms did not. These findings suggest that an 
individual’s approach to distress related to smoking cessation, rather than their absolute 
level of emotional discomfort or distress, may be a crucial factor contributing to treatment 
outcome. ACT components likewise showed considerable promise in a recent pilot study 
examining a multicomponent distress tolerance treatment for early lapsing smokers 
(Brown et al., 2008). 
The impact of ACT on substance use among poly-substance-abusing MM clients 
has also been investigated (Hayes, Wilson et al. 2004). Results revealed that compared to 
MM treatment alone, the 16-week ACT combined with MM resulted in lower opiate use 
(61% vs. 28%) and lower total drug use (50% vs. 12%) at 6-month follow up.      
To date, no study has examined whether ACT facilitates methadone 
detoxification. We present a case report of an adult MM client who received weekly 
individual ACT adjunctive to a 24-week gradual methadone dose reduction program. The 
case investigation has three purposes: (1) To illustrate how an ACT model of treatment 
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can be applied to methadone detoxification; (2) To evaluate the effect of a 6-month ACT-
enhanced methadone dose reduction program on treatment completion, opiate use, and 
the use of other illicit drugs; (3) To gather preliminary data on the relation between PI 
and treatment outcomes. If the ACT model were supported, the client would successfully 
complete the program, while showing a reduction in PI.  
Case Description 
To protect the client’s confidentiality, the identity of the client was altered. The 
client was a 57-year-old Hispanic American male with a high school education. He lived 
in a house with his second wife and her two teenage daughters in a large Southern US 
city.  The client also had two biological children, a son and daughter, from his first 
marriage. They were now adults and living independently elsewhere. The client’s first 
wife died 7 years prior from Hepatitis C contracted through heroin use. Five years after 
her death he married his current wife.  At the time of intake, the client was employed full-
time at an oil/gas factory.  
Intake screening with the Structured Clinical Interview for DSM (SCID: First, 
Spitzer, Gibbon, & Williams, 2002) and the Addiction Severity Index (ASI: McLellan, 
Luborsky, Woody, & O’Brien, 1980) revealed that the client had a history of dependence 
on alcohol (sustained full remission) and opiates (with agonist replacement therapy), and 
abuse of cocaine. The client began drinking alcohol during his adolescent years, 
eventually drinking 12-24 drinks daily.  At age 32, he attended a residential alcohol 
treatment program, which resulted in complete abstinence from alcohol thereafter.  Many 
other substances were used periodically from adolescence through his 40s including 
diazepam, barbiturates (20 yrs), marijuana (20 years), amphetamines/ methamphetamine 
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(10 years), cocaine (10 years), LSD/glue (3 years).  For a period of 17 years he reported 
using more than one substance daily. Beginning at age 40, the client began using heroin 
almost daily for 10 years and then entered MM treatment. He was at the MM clinic for 7 
years prior to voluntarily transferring to our methadone dose reduction program. Over the 
last two years the client attempted methadone detoxification at his MM clinic twice 
unsuccessfully; each time resuming his original dosing schedule within a few weeks. The 
client attributed the discontinuation of detoxification to intense withdrawal symptoms and 
emotional distresses. He reported being nervous and jittery and experienced increased 
sweating, insomnia, and depression. No other Axis I or II psychiatric disorders were 
identified. However, his score on the Beck Depression Inventory-II (BDI-II; Beck, 1996) 
was 10, indicating that he experienced slightly elevated levels of depression at the time of 
intake.  
The client was a highly appropriate candidate for methadone detoxification. He 
had a relatively stable life in that he was married, employed, and had been abstinent from 
alcohol and other drugs for at least 10 years (intake urine screen was negative for all 
substances except methadone). He displayed strong motivation for methadone 
detoxification, stating lack of freedom as his major motive. Nevertheless, he reported that 
methadone detoxification seemed extremely challenging due to withdrawal symptoms 
and previous lack of success. He had a long and extensive substance use history, and thus 
his coping seemed to be limited to avoidance and control-oriented strategies, such as 
distraction and positive-self talk; strategies intended to escape or eliminate negative 
thoughts, feelings, and bodily sensations. Given the apparent deficit of alternative skills, 
it was predicted that he would likely report withdrawal symptoms and psychological 
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distress relatively early in the course of treatment. His narrow repertoire of coping skills, 
however, seemed balanced by his strong self-reported desire to pursue personal values 
(e.g., being free). 
Setting and Staff 
The ACT-enhanced methadone detoxification was conducted in a university 
substance abuse research center staffed by interdisciplinary treatment team (e.g., nurses, 
psychiatrist, pharmacist, masters-level therapists, principal investigator, and therapist 
supervisor). The ACT therapy was conducted by a masters-level therapist with a 
cognitive-behavior therapy background who had worked in the field of substance use 
treatment for several years. She was trained and supervised in doing ACT by the second 
and third authors and on substance abuse treatment issues by the first author.   
Assessment 
 Substance Use. Throughout the course of the dose reduction program, the client’s 
substance use and subjective withdrawal experience were measured twice weekly and at 
the one-month and one-year follow-up assessments. Substance use was measured using 
Qualitative urine toxicology screens for the presence of cocaine, heroin, amphetamines, 
barbiturates, benzodiazepines, tetrahydrocannabinol, caffeine, nicotine, and methadone. 
Breath alcohol concentration (BAC) in breath samples were also measured using an 
alcohol meter (Alco Sensor 3) which detects recent alcohol use. 
Subjective Withdrawal Experience. The client’s withdrawal experience was 
assessed weekly and at both follow-up time points using the Subjective Opiate 
Withdrawal Scale (SOWS; Handelsman, Cochrane, Aronson, Ness, Rubinstein, & Kanof, 
1987). The SOWS contains items to rate the intensity of 16 different withdrawal 
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symptoms using a scale of 0 (not at all) to 4 (extremely), with greater scores suggesting 
greater subjective withdrawal experiences. The SOWS has established psychometric 
properties and provides a sensitive measure of withdrawal severity and changes in 
withdrawal severity (Gossop, 1990). Interclass correlations assessing test-retest reliability 
were significant at the p = .001 level (Handelsman et al., 1987). The SOWS items reflect: 
feeling sick, stomach cramps, muscle spasms/twitching, feelings of coldness, heart 
pounding/racing, muscle tension/feeling tense, aches and pains, yawning, runny eyes, and 
insomnia/sleeping problems.  
Negative Affect.  The BDI-II (Beck, 1996), one of the most widely used self-
report measures of depression, was administered at pretreatment and at both one-month 
and one-year follow-up time points to assess the levels of depression.   
The Detoxification Fear Survey Schedule (DFSS-27: Gentile & Milby, 1992) is a 
27-item measure of fear of relapse, withdrawal symptoms, and AIDS rated on a Likert 
scale.  The DFSS has demonstrated adequate internal consistency, ranging from .74 to .96 
and good two-week test-retest reliability (r = .77). Based on a sensitivity analysis, a cut-
off score of 70 was selected for identifying diagnostically significant and severe 
detoxification fear. The DFSS was administered monthly and at one month and one year 
follow-up time points.  
Psychological Inflexibility. The Acceptance and Action Questionnaire (AAQ; 
Hayes, Strosahl, et al., 2004) was administered monthly and at the follow-up time points  
to measure level of psychological inflexibility (PI) or  inflexible behavior repertoires, 
such as experiential avoidance, in the presence of negatively evaluated private events 
(thoughts, feelings, bodily sensation, etc). The AAQ (i.e., 9-item vesion) is a 7-point 
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Likert scale with adequate internal consistency (alpha of .70; Hayes, Strosahl, et al., 
2004).  
Program Overview 
Methadone Dose Reduction Schedule 
Based on a  previous agonist-replacement therapy detoxification study using levo-
alpha acetyl methadol (LAAM; Grabowski et al., 2005), a 24-week detoxification period 
was selected, beginning with a 4-week stabilization phase, in which methadone doses 
were adjusted based on client weight (1.2 mg/kg). The dose stabilization phase was then 
followed by a 20-week linear dose reduction phase. The client was dosed twice per week 
at the treatment-research clinic, with “take home” doses provided for the intervening 
days. This client’s initial dose was 120 mg. Some flexibility in the dose reduction 
schedule was permitted to accommodate severe withdrawal and medical concerns. For 
example, the client’s dose was held steady for an extra week in the last month of the 
detoxification due to an increase in blood pressure. 
Acceptance and Commitment Therapy 
The present ACT protocol was largely drawn from existing ACT manuals (e.g., 
Hayes et al., 1999) and the previous ACT project on polysubstance use (Hayes, Wilson, 
et al., 2004) (see Table 1). Modifications were made to reflect issues specific to 
methadone detoxification. The ACT protocol consisted of 24 50-minute sessions 
delivered weekly beginning in the stabilization period and continuing through the dose 
reduction period. Each session typically started with a 5 to 10 minute mindfulness 
exercise (e.g., breathing, sitting still, noticing and observing thoughts, feelings, bodily 
sensations). Session specific components were introduced using the client’s personal 
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experiences related to the methadone dose reduction and/or other life events.  
Implementation and rationale for the four overarching ACT intervention components are 
described generally in Table 1 and more specifically below. 
--------------------------------------------------------------------------------------- 
Insert Table 1 here 
--------------------------------------------------------------------------------------- 
Values Clarification. In contrast with several ACT protocols, values-focused 
interventions were introduced to the client early, prior to beginning the methadone dose 
reduction, for several reasons. One reason was to firmly establish ACT congruent 
treatment goals and therapeutic rationale. Clarifying the client’s personal values gave the 
therapy an overarching purpose based on what the client deemed most important.  
Methadone detoxification itself was not the end-goal, but a step in the direction of a less 
constricted and ultimately more meaningful life. Second, values-clarification was 
introduced during the stabilization period to increase the client’s motivation and 
commitment to enter into methadone detoxification. Finally, the client’s expected 
trajectory of emotional and physiological distresses throughout the course of methadone 
detoxification was taken into account for the timing of value-focused interventions. 
Greater emotional and physiological distress was expected as his dose was decreased. 
Strengthening personal values early in the treatment was thought to increase the 
probability of program completion.  
Linking the costs of previous and current substance use (and associated shame 
and guilt) with personal values was extremely powerful in the value-focused phase. For 
example, the client reported that the loss of his first wife was a most difficult and painful 
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experience for him (e.g., strong sense of guilt for introducing her to heroin). When the 
client emotionally disclosed his pain from the loss, the therapist gently said to the client:  
“It seems like you have this pain and guilt because you cared about her. You 
cared about intimacy, family, and trust. You still do. These are very important to 
you. There are values under the pain and guilt. Perhaps you are about to start 
methadone detox for this”.    
The client was well-connected to the perspective and reported his willingness to commit 
to methadone detoxification in order to have a value-directed life.    
Shifting Perspectives. Sessions 5 through 9 primarily focused on shifting 
perspectives from avoiding and controlling aversive private events (i.e., detoxification 
fear, feelings of uncertainty, fear of failure, physical withdrawal experience) to letting go 
of struggles (e.g., psychological acceptance). This was one of the most challenging tasks 
for the client. He seemed to believe, as most people do, that negative private experiences 
were likely to prevent him from staying committed to value-directed activities, including 
methadone detoxification. Given this belief, he tried not to have these events by engaging 
in distraction and positive self-talk (e.g., “I’ll be OK and stay positive!”), which seemed 
quite logical. However, these strategies were highly unlikely to help him through the 
detoxification process because distressing private experiences were simply inevitable. 
Further, avoidance and control strategies and their failure to alleviate suffering were 
likely to make these events worse, jeopardizing detoxification success. The only way to 
ultimately control the physical symptoms of withdrawal is to use methadone or heroin 
again. With this conceptualization, it was extremely crucial for the client to have the shift 
in perspective.         
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We found it helpful to suggest to the client that anxiety, depression, and physical 
withdrawal symptoms are expected given his history and that these experiences do not 
have the power to lead to the premature termination of detoxification or relapse to heroin. 
After several sessions with this focus, the client began freely admitting and sharing his 
feelings with the therapist and became open to an alternative to distraction and positive 
self-talk.   
Acceptance and Mindfulness. The stance of acceptance and mindfulness was 
introduced to the client midway through the dose-reduction schedule as the client was 
experiencing detoxification fears and subjective withdrawal symptoms at this time, but 
not to a severe degree.  For this client, more frequent voicing of his withdrawal 
symptoms (sleeplessness, leg pain, upset stomach, etc) was considered an indication of 
increased psychological acceptance, relative to his previous attempts to avoid all 
discussion of such experiences.   
In addition to using conventional ACT metaphors and experiential exercises (see 
Hayes et al, 1999), we found that the phrases “I am having the thought that…” and “I am 
noticing that ...” were useful to create distance from and reduce the attachment to his 
distressing thoughts and feelings.  These techniques helped to increase the client’s 
psychological openness and nonjudgmental stance toward these private events. The client 
learned experientially that withdrawal symptoms and negative affect did not 
automatically lead him to substance use or premature discontinuation of therapy.   
Commitment to Value-Directed Life. Sessions 18 through 24 focused on 
maintaining an ongoing commitment to value-directed actions, including methadone dose 
reduction. By week 18 of the therapy, the reduced dose of methadone resulted in highly 
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distressing withdrawal symptoms (e.g., bone pain, nausea, sweating, insomnia). The 
client’s experience of psychological and physical struggles (e.g., uncertainty, fear, pain) 
were identified, validated and normalized, and put into context with the aspects of life he 
found most important (i.e., values).  Personal values were revisited, including his 
commitment to finishing the program, to strengthen value-directed activities.  Client-
initiated value congruent actions (e.g., calling his biological son) were especially 
reinforced. In session 23 and 24, the client continued to report the gradually intensified 
experience of withdrawal symptoms. Nevertheless, he also continued to report his 
commitment to methadone detoxification and progress in communicating with his wife, 
stepdaughters, and biological children, a self-identified target behavior. In the last session, 
progress in treatment and plan for his future were discussed, and the individual therapy 
session was terminated.  
At the one-month follow-up, the client reported he was doing well, with only a 
few residual withdrawal symptoms, mainly insomnia. At one year, he and his 2nd wife 
were in the process of divorcing.  He reported increased anxiety related to this situation, 
but overall, he reported functioning well. 
Results 
Withdrawal Symptoms and Negative Affect. At intake, the client’s methadone dose 
remained stable at 120 mg, yet his SOWS score indicated moderate degrees of 
perspiration, teary eyes, running nose, and hot flushes and mild degrees of muscle aches 
(see Figure 1). Throughout the course of the 24-week methadone dose reduction program, 
his SOWS scores did not exceed pretreatment levels, despite fluctuation (i.e., ranging 
from 1 to 13). During the second half of program, his SOWS scores indicated the 
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presence of moderate stomach cramps, running nose, and anxiety. At the one-month 
follow-up, the client reported no subjective withdrawal symptoms in the SOWS.  
--------------------------------------------------------------------------------------- 
Insert Figure 1 here 
--------------------------------------------------------------------------------------- 
The client’s BDI-II score was slightly increased at the one-month follow-up 
relative to that of baseline (BDI-II = 15). The client endorsed some physiological 
symptoms of depression that overlapped with the withdrawal symptoms of methadone, 
such as fatigue and difficulty in sleeping. Increased negative affect at post-detoxificaion 
is commonly reported and often associated with relapse to opiate use (e.g., McLellan, 
Childress, Ehrman, O’Brien, & Pashko, 1986). In the midst of divorce process, he scored 
17 on BDI-II at a one-year follow-up. He endorsed past failure, loss of pleasure, and loss 
of sexual interest. 
The client’s DFSS scores at the various time points were low relative to the cut-
off score of 70 set by Milby and colleagues. Thus, although fear was reported, the client 
is not part of the minority of MM clients who report diagnostically severe detoxification 
phobia. Visual inspection of the data also indicates the client’s levels of detoxification 
fears fluctuated over time, ranging from 10 to 20 (see Figure 1). 
Psychological Inflexibility. The client’s AAQ-9 score at pretreatment (= 44) fell 
within the upper quartile (AAQ-9 > 41; Hayes, Strosahl, et al., 2004) of PI among clinical 
populations. A reduction was observed in week 4 (=38) and scores fluctuated between 40 
and 35 throughout the course of dose reduction. His average AAQ-9 score during the 
program was 38. The client scored 37 at the one-month follow-up and his AAQ at the 
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one-year follow-up was 36. Throughout the study, his score did not go below the mean of 
non-Caucasian, non-clinical population (= 34.5).   
Substance Use. Urine drug screen data revealed that the client was highly 
successful in the methadone detoxification program. No use of any substances (i.e., 
cocaine, opiates, benzodiazepines, stimulants, or psychedelics) was found during the 
entire 24-week program nor at the one-month follow-up, despite significant withdrawal 
symptoms. Once his methadone dose reached zero, urine data indicated that methadone 
was no longer present. The breath samples revealed continued abstinence from alcohol.  
These findings were also consistent with his self-report collected during the course of the 
program. At the one-year follow-up assessment, the client still remained opiate-free, yet 
reported use of prescribed benzodiazepines which was confirmed by the urine screen.    
Discussion 
Growing evidence suggests a significant impact of emotional and cognitive 
processes on substance use (Marlatt & Gordon, 1985) and the potential utility of 
acceptance-based intervention for substance-related problems (Hayes, Wilson, et al., 
2004). The present investigation reports on the first client enrolled in a treatment 
development study designed to examine the utility of ACT-based treatment for 
methadone detoxification. Positive findings indicate that, despite the well-documented 
odds against successful methadone detoxification, the client completed the program 
without relapsing to illicit substances, maintained abstinence from all substances at one-
month follow-up, and remained opiate-free one year post-treatment.   
Particularly of relevant for ACT are the elevated subjective withdrawal symptoms 
reported at intake—an entire 4 weeks before the first reduction in dose. These data 
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underscore the significance of the client’s anticipation and fear of withdrawal and other 
unpleasant detoxification experiences which manifest as anxiety-related physical 
symptoms. The presence of detoxification fear was also corroborated by a higher score at 
intake on the DFSS relative to other time points. These variables fluctuated throughout 
the course of methadone detoxification and at follow-up points, and do not seem to have 
systematic relations to substance use outcomes.  
A primary target in the ACT model is the way in which a client approaches 
difficult private events, not these events. ACT is designed to increase client’s willing to 
be open to difficult private events, while increasing value-based actions, collectively 
referred to as psychological flexibility. Although the present case report did not clearly 
show significant reduction in psychological inflexibility (PI), small changes in the 
expected direction were noted.  Future methadone detoxification studies should further 
explore the role of PI on detoxification fears, subjective withdrawal symptoms, and 
substance use outcomes. 
It may seem surprising that the client chose to use benzodiazepines reportedly due 
to emotional distress around the time of the one-year follow-up.  This result could be 
viewed as a failure of the ACT treatment or its durability, which of course are valid 
hypotheses. However, the benzodiazepine use must be viewed within the context of the 
typical methadone detoxification course and the client’s substance use history.  First, the 
success rates for methadone detoxification are dismal at best.  Most studies report high 
drop-out rates, with few patients achieving abstinence (~ 25%; Hall 1984). Some studies 
have documented that all subjects returned to methadone or other opiate use during or in 
the month following treatment (Grabowski et al., 2005). Second, this client has used 
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substances his entire life since adolescence to cope with the inevitable and difficult 
experiences of life. He used almost every class of drug available and became 
physiologically dependent at different times on alcohol and heroin. Within this context, 
the fact that the client went to a doctor and acquired a prescription for an anti-anxiety 
medication (a behavior engaged in by many Americans), versus returning to opiates or 
other illicit drugs, can arguably be viewed as responsible behavior in the context of a 
distressing environmental situation (divorce)—a significant accomplishment for this 
client. Of course, if the client used the medication such that it began to interfere with 
pursing important life values, then the durability of ACT may be questioned and the need 
for booster sessions may be entertained. If the client uses benzodiazepines for a period of 
time without negative consequences in other life domains, however, we would not 
consider him a treatment failure.    
Methodologically, it should be noted that although reductions in PI were found 
using the general, non-problem-specific AAQ, the decrements were not large. Failure to 
find large changes on the general AAQ has been reported in other studies as well (e.g., 
Hayes et al., 2006). A measure of psychological inflexibility related to the experience of 
methadone detoxification may more precisely capture the specific fears and avoidance 
strategies typical of the population. Future research is needed to develop and test such a 
measure.   
It is important to note that there are competing explanations for treatment success. 
The first factor is simply age. The client was 57 years old, and based on the typical 
course of substance abuse, he was more likely to achieve abstinence from drugs 
compared to substance users in younger age groups. It is important to note, however, that 
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he failed detoxification twice in very recent years, and that many other clients in our 
substance abuse clinic of similar age have not succeeded to this level. Another factor that 
could influence treatment outcome is the dose-reduction schedule. The duration of the 
preset dose reduction program (i.e., 24 weeks) was longer than those used in most 
previous studies (e.g., 3, 6, or 12 weeks). Positive results in the present case might be 
simply due to the longer period of gradual dose reduction. Perhaps even more importantly 
is that this client was abstinent from all other substances upon commencing the 
detoxification program. This is not the norm in the methadone-using population and may 
have played a large role in his ability to achieve and maintain opiate abstinence.   
Thus, further study with methodological rigor is needed to determine whether the 
ACT-enhanced methadone dose reduction is effective for more complicated MM clients. 
Exploration of client characteristics indicative of success with the ACT-based treatment 
also seems warranted, particularly examining the relation between PI and treatment 
outcomes. Given the results of the present case study, it seems worthwhile to continue 
research on this promising behavioral therapy for the methadone-using population.  
Finally, it is important to acknowledge that methadone dose reduction is 
extremely complicated. The physical and psychological distress experienced by these 
clients should not be underestimated. Although there is much research to be done to 
determine the conditions under which clients will benefit from methadone detoxification, 
the present case suggests that there are MM clients who can successfully detoxify and 
lead drug-free lives. Researchers have an obligation to better understand the process in 
order to develop more precisely focused and effective treatments.  
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Table 1.  Overview of ACT Components and Strategies 
Sessions Components/Strategies Goals/Purposes 
1-4 • Rapport Building 
 
 
• Choosing a valued 
direction (value 
clarification) 
 
• Client and therapist develop ACT-consistent treatment 
alliances and goals. 
 
• Client identifies values and increases motivation for 
having a value-directed life as well as commitment to 
methadone detoxification. 
 
5-9 • Shifting Perspective: 
Control is the problem 
 
 
 
 
 
 
 
 
 
 
 
• Letting go of struggle 
• Client identifies his previous and current coping styles 
for difficult psychological events (e.g., anxiety, self-
doubt, fear, negative bodily sensation, etc). 
• Client learns these coping strategies are for controlling 
and avoiding negative psychological events.  
• Client learns that these coping strategies are not 
working well in the long run.  
• Client explores ways in which control and avoidance 
attempts prevent him from engaging in value-directed 
behaviors.  
• Attempts to control and avoid problematic private 
events might have negative iatrogenic effects. 
 
• Client notices the futility of control and avoidance 
attempts and is willing to consider an alternative 
approach to his difficult private events (e.g., fear of 
uncertainty, fear of failure).  
 
10-18 • Acceptance and 
Mindfulness 
 
 
 
 
 
 
 
• Client learns psychological acceptance as an 
alternative to avoidance and control attempts.  
• Client chooses to be open to or to allow whatever he is 
experiencing as it is (i.e., acceptance), even difficult 
psychological events. 
• Client learns to observe his private events.  
• Client learns not to get sidetracked by his difficult 
psychological events. 
19-24 • Commitment • Client progresses toward a committed and value-
directed life (e.g., the completion of methadone 
detoxification).  
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Figure Caption 
Figure 1. Methadone dose schedule, subjective opiates withdrawal experiences, 
detoxification fear, and psychological inflexibility throughout the course of ACT-
enhanced methadone detoxification program. 
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